A Pilot Study to Develop Predictive Biomarkers for the Response to Immunotherapy in Lung Cancer

Abramson Cancer Center at Penn Medicine88 enrolled

Overview

Several immune checkpoint inhibitors targeting the PD-1 pathway have been developed with clinical trials showing an approximately 20% durable response in unselected patients with advanced non-small cell lung cancer (NSCLC). At the moment, no clear biomarker exists to accurately predict anti-PD1/PDL1 tumor responsiveness. The goal of this study is to broadly discover and evaluate the utility of blood based biomarkers for use in measuring and predicting response to immunotherapy in patients with lung cancer.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Lung Cancer

Interventions

Blood and Urine CollectionOTHER

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Advanced Metastatic NSCLC * Scheduled to initiate an immune checkpoint inhibitor * Age \>= 18 years * Able to provide informed consent Exclusion Criteria: * Other, unrelated, concomitant active, invasive malignancy

Locations (1)

Abramson Cancer Center of the University of Pennsylvania

Philadelphia, Pennsylvania, United States

Outcomes

Primary Outcomes

the correlation between markers identified in the blood and in the primary tumor.

Time frame: 5 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.